You’re mid–Q-bank grind, and a seemingly simple biochem stem hits you with a curveball: a kid with self-injury and kidney stones. You think you know it’s Lesch-Nyhan… but the question asks about a specific enzyme, metabolite, or pathway consequence—and suddenly every answer choice looks plausible. This post is about turning that “I recognize it” into “I can’t miss it,” by breaking down the correct answer and why each distractor is wrong.
The Classic Vignette (What They’re Really Testing)
Stem you should instantly pattern-match:
- Young boy with developmental delay
- Self-mutilation (biting lips/fingers), aggression
- Dystonia/choreoathetosis
- Orange “sand” in diaper or recurrent kidney stones
- Labs: hyperuricemia
- X-linked recessive
Diagnosis: Lesch-Nyhan syndrome
Core defect: HGPRT deficiency → impaired purine salvage
Tag: Biochemistry > DNA/RNA/Nucleic Acids
The “One-Line” Pathophys (But Make It Testable)
Normal purine salvage (high yield)
- HGPRT salvages:
- Hypoxanthine → IMP
- Guanine → GMP
- Uses PRPP as a ribose-phosphate donor.
Lesch-Nyhan: what breaks
- ↓ IMP and ↓ GMP (from salvage)
- ↑ PRPP
- ↓ feedback inhibition of de novo purine synthesis (because IMP/GMP are low)
- Net effect: increased de novo purine synthesis → more purines to degrade → ↑ uric acid
A useful way to remember the “direction”:
- Salvage down → PRPP up → de novo up → uric acid up
Likely Question Formats (And the Correct Answer Logic)
If the question asks: “Which enzyme is deficient?”
Correct: Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)
Why: This is the defining defect and best explains both neurologic symptoms and hyperuricemia due to increased purine turnover.
If the question asks: “Which metabolite is increased?”
Most testable “increases”:
- PRPP ↑
- Uric acid ↑
- De novo purine synthesis ↑
If the question asks: “Which nucleotide levels are decreased?”
- IMP ↓ and GMP ↓ (from impaired salvage)
Q-Bank Breakdown: Every Answer Choice Matters
Below are common distractors that show up with Lesch-Nyhan stems—and exactly how to eliminate them.
Distractor 1: Adenosine deaminase (ADA) deficiency
Why they tempt you: ADA is also a purine disorder and shows up in “nucleic acids” content.
Why it’s wrong here:
- ADA deficiency → SCID
- Recurrent infections
- Chronic diarrhea
- Thrush
- Failure to thrive
- Mechanism: ↑ deoxyadenosine → ↑ dATP → inhibits ribonucleotide reductase → impaired DNA synthesis in lymphocytes
Key separator:
- Lesch-Nyhan = self-mutilation + hyperuricemia
- ADA deficiency = severe infections (SCID)
Distractor 2: Xanthine oxidase deficiency
Why they tempt you: XO is directly involved in making uric acid.
Why it’s wrong here:
- XO deficiency → low uric acid, ↑ xanthine (can cause xanthine stones, but uric acid won’t be high)
- Lesch-Nyhan is hyperuricemia from excess purine production and breakdown.
Board-style clue:
If the stem explicitly says low uric acid or xanthine stones, think XO deficiency—not Lesch-Nyhan.
High-yield tie-in:
XO is inhibited by allopurinol and febuxostat (gout treatment). Lesch-Nyhan patients may be treated for hyperuricemia with XO inhibitors, but that’s treatment—not the underlying defect.
Distractor 3: PRPP synthetase overactivity
Why they tempt you: It also causes hyperuricemia via increased de novo purine synthesis.
Why it’s wrong here:
- PRPP synthetase overactivity classically → gout, uric acid stones, sometimes neuro findings—but not the hallmark self-mutilation phenotype.
- Lesch-Nyhan is a very specific neurobehavioral syndrome due to HGPRT deficiency.
How to differentiate in one step:
- Self-injury + dystonia/choreoathetosis = HGPRT deficiency
- “Gouty guy” without the classic neurobehavioral picture = consider PRPP synthetase overactivity
Distractor 4: Ornithine transcarbamylase (OTC) deficiency
Why they tempt you: Both are X-linked and can present in infants with neurologic symptoms.
Why it’s wrong here:
- OTC deficiency → hyperammonemia, not hyperuricemia
- Labs: ↑ orotic acid, ↓ BUN, respiratory alkalosis early
- Presentation: poor feeding, vomiting, lethargy, seizures, cerebral edema
Quick elimination rule:
If the stem gives ammonia abnormalities, you’re in urea cycle, not purine salvage.
Distractor 5: Phenylalanine hydroxylase deficiency (PKU)
Why they tempt you: Neuro findings in a child + classic Step content.
Why it’s wrong here:
- PKU hallmark clues:
- Musty/mousy odor
- Eczema
- Fair skin (↓ melanin)
- Intellectual disability if untreated
- Not associated with hyperuricemia or self-mutilation
Distractor 6: Adenine phosphoribosyltransferase (APRT) deficiency
Why they tempt you: Another “salvage enzyme” answer choice.
Why it’s wrong here:
- APRT salvages adenine → AMP
- Deficiency → rare; can cause 2,8-dihydroxyadenine stones
- Does not cause the classic Lesch-Nyhan neurobehavioral phenotype
Exam move:
If they want Lesch-Nyhan, they usually specify hypoxanthine/guanine salvage or HGPRT directly.
High-Yield Table: Lesch-Nyhan vs Common Look-Alikes
| Disorder | Key Enzyme/Defect | Core Findings | Labs |
|---|---|---|---|
| Lesch-Nyhan | HGPRT deficiency (XLR) | Self-mutilation, dystonia, aggression, gout/kidney stones | ↑ uric acid, ↑ PRPP, ↓ IMP/GMP (salvage) |
| ADA deficiency | ADA deficiency (AR) | SCID, recurrent infections | Lymphopenia; ↑ deoxyadenosine, ↑ dATP |
| XO deficiency | Xanthine oxidase deficiency | Xanthine stones, myopathy (rare) | ↓ uric acid, ↑ xanthine |
| PRPP synthetase overactivity | Increased PRPP production | Gout, stones | ↑ uric acid, ↑ de novo purines |
| OTC deficiency | Urea cycle defect (XLR) | Encephalopathy in infant | ↑ ammonia, ↑ orotic acid |
The Mechanism They Love to Test (Feedback Matters)
In Lesch-Nyhan:
- ↓ HGPRT → ↓ IMP and ↓ GMP (salvage products)
- Normally, IMP/GMP help inhibit de novo purine synthesis
- Without them, de novo synthesis ramps up
Conceptually:
- PRPP is the “gas pedal” for de novo purine synthesis.
- Loss of salvage means PRPP accumulates and keeps driving the pathway.
Micro–Pearls That Win Points on Test Day
- Inheritance: X-linked recessive → often a boy with severe phenotype.
- Neurobehavioral hallmark: self-mutilation is the clue that should outweigh “generic” gout answers.
- Metabolic endpoint: excess purine synthesis → breakdown → uric acid (gout, nephrolithiasis).
- Common stem detail: “orange crystals” in diaper = urate crystals.
- Treatment nuance (Step-level):
- XO inhibitors (e.g., allopurinol/febuxostat) can reduce uric acid complications
- They do not fix neurologic symptoms (those are not simply “urate toxicity”)
Takeaway (How to Stop Missing These)
When you see Lesch-Nyhan, lock in this chain:
HGPRT deficiency → ↓ purine salvage → ↑ PRPP + ↓ IMP/GMP feedback → ↑ de novo purines → ↑ uric acid + neurobehavioral syndrome (self-mutilation).
Then use the stem’s “anchor clue” (self-injury + hyperuricemia) to demolish distractors that are only loosely related to nucleic acid metabolism.